HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Rathi N PillaiMadhusmita BeheraLynne D BerryMike R RossiMark G KrisBruce E JohnsonPaul A BunnSuresh R RamalingamFadlo R KhuriPublished in: Cancer (2017)
HER2 mutations were detected in 3% of patients with lung adenocarcinoma in the LCMC. HER2-directed therapies should be investigated in this subgroup of patients. Cancer 2017;123:4099-4105. © 2017 American Cancer Society.